Home › Compare › MYTHF vs ABBV
MYTHF yields 2.09% · ABBV yields 3.06%● Live data
📍 MYTHF pulled ahead of the other in Year 4
Combined, MYTHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MYTHF + ABBV for your $10,000?
Mytilineos S.A. operates in metallurgy, sustainable engineering solution, renewables and storage development, and power and gas sectors in Greece, the European Union, and internationally. Its principal business areas include the production of electricity and natural gas; operation of industrial and renewable energy plants; trading of gas; production of alumina and aluminum, as well as bauxite and recycled aluminum; and production, processing, and trading of metals, which include aluminum alloys and derivative products. The company also engages in the development and contract of solar and energy storage projects; contract of specialized large-scale integrated turn-key projects; construction of infrastructure projects; and provision of photovoltaic construction, as well as environmental solutions for water, liquid, and solid waste. In addition, it provides energy solutions; and a range of project management, engineering, procurement, construction, and plant commissioning services. The company was formerly known as Mytilineos Holdings S.A. and changed its name to Mytilineos S.A. in July 2019. Mytilineos S.A. was founded in 1908 and is headquartered in Athens, Greece.
Full MYTHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.